AMD Action, an initiative being spearheaded by advocacy
groups, physicians and government representatives from 21 countries,
issued today a "Call to Action" to address the increasing incidence of
age-related macular degeneration (AMD) - a debilitating eye condition
which can rapidly lead to blindness.
"We call upon governments, medical, professional and consumer
groups to recognise the increasing burden of AMD-related blindness and
to address the crisis with urgency by promoting and supporting:
-- Education,
-- Prevention,
-- Early detection,
-- Timely access to treatment for all,
-- Rehabilitation and social services, and
-- Research."
More than 100 international experts in age-related blindness
developed the "Call to Action" at a Summit organised by the AMD
Alliance International (AMDAI) and the AMD Action Global Steering
Committee.
Steve Winyard, AMDAI Chairman and Head of Public Policy, Royal
National Institute of the Blind, UK commented, "AMD hits particularly
hard in areas with rapidly ageing populations, such as Europe. Each
year there are an estimated 500,000 new cases of wet AMD worldwide, so
it is crucially important to increase awareness and understanding of
the disease so that people can make informed lifestyle choices to
reduce both vision loss and associated costs. In the five largest
countries in Europe, the average annual cost of AMD in the EU ranges
between 700 million euros and three billion euros."(1)
AMD affects between 25 and 30 million people globally and is the
leading cause of blindness in developed countries.(2)
As the "baby boom" generation ages, the incidence of AMD is
expected to triple by the year 2025.(3)
Patients with the wet form of AMD can become blind in as little as
three months if not treated early.(4)
Yet awareness and understanding of AMD is low. A recent European
AMD awareness survey revealed 80 percent of the population had not
heard of wet AMD and only 38 percent recognised smoking as a risk
factor for the disease.(5)
"Both the incidence and prevalence of AMD is increasing. There are
new treatments becoming available that can help prevent vision loss
but early treatment with these therapies is the key. It is therefore
vital that physicians have access to safe, effective, licensed
treatments that can really help maintain the independence of AMD
patients for as long as possible," said Dr Alan Cruess, AMD Action
Summit Moderator and Professor and Head Department of Ophthalmology &
Visual Sciences Dalhousie University, Canada.
Day two of the AMD Action Summit focuses the delegates on
developing national level action plans to tackle challenges specific
to their countries.
Notes to Editors
The AMD Alliance International is a non-profit coalition of
vision, research and seniors organisations working to raise awareness
of AMD, of treatment and rehabilitation options and of the importance
of early detection. Alliance membership currently includes 55
non-profit organisations from 21 countries, including world-renowned
leaders in ophthalmology, vision rehabilitation, patient and senior's
advocacy, and research.
Together with the AMD Alliance International, the AMD Action
Summit has been developed in partnership and with the support of world
leading ophthalmologists and advocacy groups. The Global Steering
Committee comprises Dr Hugh Taylor (Australia), Dr Alan Cruess
(Canada), Prof Usha Chakravarthy (Ireland), Prof Frank Holz (Germany),
RNIB (UK), Macular Degeneration Foundation (Australia), CNIB (Canada),
Retina International, Pro Retina Germany, IAPB Italy and Retina France
International.
The AMD Awareness Survey was conducted in February 2006. The
countries included were the United Kingdom, France, Spain, Germany,
Italy and Canada and involved 3,675 respondents. The survey was
designed to examine the level of awareness of AMD including its
symptoms and modifiable risk factors.
The AMD Action Summit has been made possible with funding from
Pfizer Ophthalmics.
(1)AMD BOI Study: Pfizer data on file
(2)WHO: Magnitude and causes of visual impairment. Factsheet 282.
November 04
(3)AMD Alliance International Website
http://www.amdalliance.com/media/media-kit/amd-facts.asp
(4)AMD Alliance International Campaign Report 2003. Country
Reports on Early Detection and Low Vision Rehabilitation
(5)Pfizer data on file
